Bollen L J, Tjong-A-Hung S P, van der Velden J, Mol B W, Lammes F B, ten Kate F W, ter Schegget J, Bleker O P
Department of Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, The Netherlands.
Cancer. 1996 Jun 15;77(12):2538-43. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2538::AID-CNCR17>3.0.CO;2-T.
The presence of human papillomavirus (HPV) DNA in relation to cervical cytology was evaluated after treatment of cervical dysplasia.
Forty patients, 22 with normal and 18 with abnormal cytology (mild or moderate dyskaryosis), with a history of cervical dysplasia were selected. Only patients with HPV DNA positive biopsies obtained before treatment were included. The presence of HPV was assessed in cervical smears at least 1 year after treatment of cervical dysplasia by using a polymerase chain reaction (PCR) with consensus primers (CPI/IIG). HPV typing was done by direct sequence analysis of the CPI/IIG PCR generated amplimers.
Smears from 3 of the 22 patients with normal cytology after treatment were positive for HPV DNA (14%). HPV DNA positive smears were found in 13 of the 18 patients with abnormal cytology after treatment (72%) (relative risk: 5.3; 95% confidence interval: 1.78-15.75). In 11 of the 16 HPV DNA positive smears (69%), the HPV type was different from that before treatment. In 35 of 40 patients, the HPV type before treatment could not be detected after treatment (88%).
A minority of the patients with normal cytology after treatment of cervical dysplasia had detectable HPV DNA. In contrast, a high prevalence of HPV DNA was found in cervical smears of patients with abnormal cytology after treatment of cervical dysplasia. After treatment, none of the patients with abnormal cytology but HPV DNA negative smears had recurrence of cervical intraepithelial neoplasia. This suggests the value of supplementary HPV DNA testing during follow-up of patients treated for cervical dysplasia.
在宫颈发育异常治疗后，评估人乳头瘤病毒（HPV）DNA与宫颈细胞学的关系。
选取40例有宫颈发育异常病史的患者，其中22例细胞学正常，18例细胞学异常（轻度或中度核异质）。仅纳入治疗前活检HPV DNA阳性的患者。在宫颈发育异常治疗后至少1年，通过使用共识引物（CPI/IIG）的聚合酶链反应（PCR）评估宫颈涂片HPV的存在情况。通过对CPI/IIG PCR产生的扩增子进行直接序列分析来进行HPV分型。
治疗后22例细胞学正常的患者中，3例涂片HPV DNA阳性（14%）。治疗后18例细胞学异常的患者中，13例涂片HPV DNA阳性（72%）（相对风险：5.3；95%置信区间：1.78 - 15.75）。16例HPV DNA阳性涂片中，11例（69%）的HPV类型与治疗前不同。40例患者中，35例（88%）治疗后未检测到治疗前的HPV类型。
宫颈发育异常治疗后细胞学正常的患者中，少数可检测到HPV DNA。相反，宫颈发育异常治疗后细胞学异常的患者宫颈涂片中HPV DNA患病率较高。治疗后，细胞学异常但HPV DNA涂片阴性的患者均无宫颈上皮内瘤变复发。这表明在宫颈发育异常治疗患者的随访中进行补充HPV DNA检测的价值。
